Regeneron Tops Roche in Eye Drug Study That May Boost Sales
This article is for subscribers only.
Regeneron Pharmaceuticals Inc.’s injection Eylea helped patients with severe eye disease caused by diabetes more than two Roche Holding AG medicines in the first head-to-head study of the drugs.
The finding may lead to doctors shifting more patients with diabetic macular edema to more-expensive Eylea, a boost for Regeneron since the drug generates about two-thirds of the company’s sales. Eylea performed significantly better than the Roche drugs in people with moderate to severe vision loss, making it the preferred choice, said Daniel Martin, chairman of the Cleveland Clinic’s Cole Eye Institute.